Brandywine Global Investment Management LLC Acquires 8,823 Shares of Halozyme Therapeutics, Inc. $HALO

Brandywine Global Investment Management LLC boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 12.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 81,836 shares of the biopharmaceutical company’s stock after purchasing an additional 8,823 shares during the period. Brandywine Global Investment Management LLC’s holdings in Halozyme Therapeutics were worth $5,508,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Larson Financial Group LLC raised its holdings in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares during the last quarter. Measured Wealth Private Client Group LLC raised its stake in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares during the last quarter. Clearstead Advisors LLC raised its stake in shares of Halozyme Therapeutics by 107.7% during the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 265 shares during the last quarter. Harbour Investments Inc. raised its stake in shares of Halozyme Therapeutics by 152.5% during the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 372 shares during the last quarter. Finally, Wexford Capital LP bought a new position in shares of Halozyme Therapeutics during the third quarter valued at about $70,000. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Down 1.4%

Shares of NASDAQ HALO opened at $70.50 on Thursday. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. Halozyme Therapeutics, Inc. has a 12 month low of $51.06 and a 12 month high of $82.22. The firm has a market capitalization of $8.36 billion, a PE ratio of 25.36, a price-to-earnings-growth ratio of 0.30 and a beta of 0.88. The firm has a fifty day simple moving average of $67.31 and a two-hundred day simple moving average of $68.75.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, topping the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business had revenue of $376.71 million during the quarter, compared to analyst estimates of $358.60 million. During the same period in the prior year, the business earned $1.11 EPS. The company’s revenue for the quarter was up 42.2% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities analysts expect that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current year.

Analyst Ratings Changes

HALO has been the topic of a number of research analyst reports. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. HC Wainwright boosted their price target on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, May 12th. UBS Group restated a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Finally, Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Eight equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $81.60.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $66.21, for a total value of $107,591.25. Following the completion of the transaction, the director directly owned 43,669 shares in the company, valued at approximately $2,891,324.49. This represents a 3.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the completion of the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at $51,886,572.40. This trade represents a 2.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 93,250 shares of company stock valued at $6,299,746 over the last 90 days. Company insiders own 2.50% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.